Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Syros Reports Third Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
November 1, 2018 7:00 AM EDTOpened Expansion Cohorts in Phase 1 Trial Evaluating SY-1365 in Multiple Ovarian and Breast Cancer Populations as Single Agent and in Combination
Selected Oral CDK7 Inhibitor SY-5609 as Development Candidate to Enter IND-Enabling Studies
Dose Escalation Data from Phase 1 Trial of SY-1365 to be Presented at EORTC-NCI-AACR and Initial Clinical Data from Combination Arms of Phase 2 Trial of SY-1425 to be Presented at ASH
Management to Host Conference Call at 7:30 AM ET Today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:... More
